JP2010507786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507786A5 JP2010507786A5 JP2009533659A JP2009533659A JP2010507786A5 JP 2010507786 A5 JP2010507786 A5 JP 2010507786A5 JP 2009533659 A JP2009533659 A JP 2009533659A JP 2009533659 A JP2009533659 A JP 2009533659A JP 2010507786 A5 JP2010507786 A5 JP 2010507786A5
- Authority
- JP
- Japan
- Prior art keywords
- acute coronary
- marker
- coronary syndrome
- myocardial infarction
- proanp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 41
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 31
- 206010002383 Angina Pectoris Diseases 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 239000003550 marker Substances 0.000 claims description 21
- 102100034296 Natriuretic peptides A Human genes 0.000 claims description 20
- 102400000061 Neurophysin 2 Human genes 0.000 claims description 20
- 108010018674 Neurophysins Proteins 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 20
- 102400000060 Copeptin Human genes 0.000 claims description 18
- 101800000115 Copeptin Proteins 0.000 claims description 18
- 238000013517 stratification Methods 0.000 claims description 16
- -1 NT-proANP Proteins 0.000 claims description 14
- 238000004393 prognosis Methods 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 12
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 12
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 12
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 11
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 102400001263 NT-proBNP Human genes 0.000 claims description 10
- 101710187800 Natriuretic peptides A Proteins 0.000 claims description 10
- 239000002934 diuretic Substances 0.000 claims description 10
- 230000001452 natriuretic effect Effects 0.000 claims description 10
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 102100036836 Natriuretic peptides B Human genes 0.000 claims description 8
- 101710187802 Natriuretic peptides B Proteins 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 6
- 102100032752 C-reactive protein Human genes 0.000 claims description 6
- 238000003748 differential diagnosis Methods 0.000 claims description 6
- 238000013399 early diagnosis Methods 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000002644 neurohormonal effect Effects 0.000 claims description 4
- 108010012004 proadrenomedullin Proteins 0.000 claims description 4
- 102000034567 proadrenomedullin Human genes 0.000 claims description 4
- 102000004903 Troponin Human genes 0.000 claims description 3
- 108090001027 Troponin Proteins 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 101800000285 Big gastrin Proteins 0.000 claims description 2
- 102000004420 Creatine Kinase Human genes 0.000 claims description 2
- 108010042126 Creatine kinase Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 102400000569 Myeloperoxidase Human genes 0.000 claims description 2
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 2
- 102000036675 Myoglobin Human genes 0.000 claims description 2
- 108010062374 Myoglobin Proteins 0.000 claims description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 claims description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 claims description 2
- 102100028427 Pro-neuropeptide Y Human genes 0.000 claims description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 2
- 108010048233 Procalcitonin Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 239000013610 patient sample Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 claims description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 2
- 108010072272 proendothelin 1 Proteins 0.000 claims description 2
- 108010088603 proneuropeptide Y Proteins 0.000 claims description 2
- 108010001670 prosomatostatin Proteins 0.000 claims description 2
- GGYTXJNZMFRSLX-UHFFFAOYSA-N prosomatostatin Chemical compound C1CCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NCC(=O)NC2C(NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C4=CC=CC=C4NC=3)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(C(=O)NC(CO)C(=O)NC(CSSC2)C(O)=O)C(C)O)C(C)O)=O)N1C(=O)C(C)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C1CCCN1C(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(N)CO GGYTXJNZMFRSLX-UHFFFAOYSA-N 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 102000013394 Troponin I Human genes 0.000 claims 1
- 108010065729 Troponin I Proteins 0.000 claims 1
- 102000004987 Troponin T Human genes 0.000 claims 1
- 108090001108 Troponin T Proteins 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE200610050497 DE102006050497A1 (de) | 2006-10-26 | 2006-10-26 | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
| DE102006050497.6 | 2006-10-26 | ||
| DE102006057409.5 | 2006-12-04 | ||
| DE200610057409 DE102006057409A1 (de) | 2006-12-04 | 2006-12-04 | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
| PCT/DE2007/001928 WO2008049422A2 (de) | 2006-10-26 | 2007-10-26 | Risikostratifizierung des akuten koronarsyndroms mittels fragmenten / teilpeptiden des provasopressins, insbesondere copeptin oder neurophysin ii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013077587A Division JP2013178249A (ja) | 2006-10-26 | 2013-04-03 | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010507786A JP2010507786A (ja) | 2010-03-11 |
| JP2010507786A5 true JP2010507786A5 (enExample) | 2011-11-24 |
| JP5320294B2 JP5320294B2 (ja) | 2013-10-23 |
Family
ID=39276269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533659A Active JP5320294B2 (ja) | 2006-10-26 | 2007-10-26 | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 |
| JP2013077587A Pending JP2013178249A (ja) | 2006-10-26 | 2013-04-03 | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013077587A Pending JP2013178249A (ja) | 2006-10-26 | 2013-04-03 | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8501485B2 (enExample) |
| EP (1) | EP2084543B1 (enExample) |
| JP (2) | JP5320294B2 (enExample) |
| DE (1) | DE112007003185A5 (enExample) |
| DK (1) | DK2084543T3 (enExample) |
| ES (1) | ES2652027T3 (enExample) |
| PL (1) | PL2084543T3 (enExample) |
| WO (1) | WO2008049422A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| US8129135B2 (en) * | 2006-04-24 | 2012-03-06 | Medizinische Universität Wien | Method for diagnosing cardiovascular diseases |
| JP5320294B2 (ja) * | 2006-10-26 | 2013-10-23 | ベー．エル．アー．ハー．エム．エス ゲーエムベーハー | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 |
| DE102006058266A1 (de) * | 2006-12-08 | 2008-06-12 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| EP2356450B1 (en) | 2008-10-24 | 2019-02-06 | B.R.A.H.M.S GmbH | Prognosis and risk assessment in stroke patients by determining the level of marker peptides |
| JP5785086B2 (ja) * | 2008-10-31 | 2015-09-24 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
| CN102428368B (zh) * | 2009-05-05 | 2015-04-22 | B.R.A.H.M.S有限公司 | 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层 |
| RU2017110678A (ru) * | 2010-11-01 | 2019-01-24 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
| EP2533052A1 (en) * | 2011-06-07 | 2012-12-12 | B.R.A.H.M.S GmbH | Diagnostic use of proSomatostatin |
| WO2013036913A1 (en) * | 2011-09-08 | 2013-03-14 | Nexus Dx, Inc. | A multilevel analyte assay |
| WO2017136464A1 (en) | 2016-02-01 | 2017-08-10 | Prevencio, Inc. | Diagnostic and prognostic methods for cardiovascular diseases and events |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| KR102318236B1 (ko) * | 2020-02-18 | 2021-10-26 | 한림대학교 산학협력단 | 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305142D0 (en) * | 1993-03-12 | 1993-04-28 | Medinnova Sf | Method |
| DE60233301D1 (de) | 2001-05-04 | 2009-09-24 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| MXPA03004105A (es) | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| DE60335387D1 (de) * | 2002-07-16 | 2011-01-27 | Woomera Therapeutics Inc | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen |
| CA2485722A1 (en) * | 2003-10-22 | 2005-04-22 | Paul Lehmann | Soluble transferrin receptor |
| EP1530047A1 (en) * | 2003-11-07 | 2005-05-11 | Roche Diagnostics GmbH | Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102004051847B4 (de) * | 2004-10-25 | 2008-09-18 | Dade Behring Marburg Gmbh | Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen |
| EP2302395B1 (en) * | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| JP5320294B2 (ja) * | 2006-10-26 | 2013-10-23 | ベー．エル．アー．ハー．エム．エス ゲーエムベーハー | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 |
| DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006058266A1 (de) * | 2006-12-08 | 2008-06-12 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| EP2148203A1 (en) * | 2008-07-23 | 2010-01-27 | BRAHMS Aktiengesellschaft | Azurophilic granule proteases as markers in cardiological diseases |
| EP2356450B1 (en) * | 2008-10-24 | 2019-02-06 | B.R.A.H.M.S GmbH | Prognosis and risk assessment in stroke patients by determining the level of marker peptides |
-
2007
- 2007-10-26 JP JP2009533659A patent/JP5320294B2/ja active Active
- 2007-10-26 PL PL07846265T patent/PL2084543T3/pl unknown
- 2007-10-26 EP EP07846265.2A patent/EP2084543B1/de active Active
- 2007-10-26 DE DE112007003185T patent/DE112007003185A5/de not_active Withdrawn
- 2007-10-26 DK DK07846265.2T patent/DK2084543T3/en active
- 2007-10-26 WO PCT/DE2007/001928 patent/WO2008049422A2/de not_active Ceased
- 2007-10-26 US US12/447,105 patent/US8501485B2/en active Active
- 2007-10-26 ES ES07846265.2T patent/ES2652027T3/es active Active
-
2013
- 2013-04-03 JP JP2013077587A patent/JP2013178249A/ja active Pending
- 2013-07-25 US US13/951,084 patent/US9261517B2/en active Active
-
2016
- 2016-01-21 US US15/003,734 patent/US10254289B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507786A5 (enExample) | ||
| JP2010513880A5 (enExample) | ||
| JP5320294B2 (ja) | プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化 | |
| JP5190067B2 (ja) | Ｎｔ−プロｂｎｐと組み合わせてのｃｔ−プロｅｔ−１による急性冠症候群の診断および危険性の分類 | |
| JP2010513879A5 (enExample) | ||
| ES2455191T3 (es) | Procedimiento para determinar la parte de la región media de proANP amino-terminal en pacientes que presentan una cardiopatía o que se sospecha que desarrollan o que presentan una cardiopatía | |
| JP3783002B2 (ja) | マーカーの組み合わせを用いた心臓疾患症例の予後判定 | |
| KR101245877B1 (ko) | Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법 | |
| Ray et al. | Combined copeptin and troponin to rule out myocardial infarction in patients with chest pain and a history of coronary artery disease | |
| RU2672561C2 (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| JP2010520442A (ja) | Ｎｙｈａｉ患者についてのナトリウム利尿ペプチドによる心機能不全の診断および危険性層化 | |
| JP2010509575A5 (enExample) | ||
| JP2012508386A (ja) | Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 | |
| JP6412085B2 (ja) | トロポニンおよびｂｎｐに基づく発作のリスク患者および原因の診断 | |
| JP2020034564A (ja) | 心不全リスクの予測改善のためのバイオマーカー | |
| KR20190039970A (ko) | 심방 세동 및 졸중의 평가에서 순환성 esm-1 (엔도칸) | |
| Sawicki et al. | Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes | |
| JP2010511877A5 (enExample) | ||
| JP5388858B2 (ja) | ニューロフィジンを使用する心機能不全の診断および危険性の層化 | |
| Sinning et al. | Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients | |
| Zurek et al. | Midregional pro-adrenomedullin and copeptin: exercise kinetics and association with the cardiopulmonary exercise response in comparison to B-type natriuretic peptide | |
| CN101600967B (zh) | 和肽素或后叶激素运载蛋白ii在制备急性冠状动脉综合征危险性分级试剂盒的用途 | |
| Hammarsten et al. | Copeptin: A new peptide in clinical measurement | |
| HK1135185B (en) | Kit for diagnosis and risk stratification of cardiac insufficiency using neurophysin |